BR0317879A - Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo - Google Patents

Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo

Info

Publication number
BR0317879A
BR0317879A BR0317879-0A BR0317879A BR0317879A BR 0317879 A BR0317879 A BR 0317879A BR 0317879 A BR0317879 A BR 0317879A BR 0317879 A BR0317879 A BR 0317879A
Authority
BR
Brazil
Prior art keywords
rotavirus
protein
cancer
monoclonal
therapeutic agent
Prior art date
Application number
BR0317879-0A
Other languages
English (en)
Inventor
Lorenza Gonzalez-Mariscal
Porfirio Nova-Dominguez
Original Assignee
Ct Investig Y Estudios Del Ipn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Investig Y Estudios Del Ipn filed Critical Ct Investig Y Estudios Del Ipn
Publication of BR0317879A publication Critical patent/BR0317879A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USOS DA PROTEìNA VP4 DE ROTAVìRUS E DE ANTICORPOS MONOCLONAIS OU POLICLONAIS, COMPOSIçãO FARMACêUTICA, AGENTE TERAPêUTICO, MEDICAMENTOS, MéTODOS PARA TRATAR DIABETE E CâNCER, PARA REDUZIR A ADESãO CELULAR NãO DESEJADA QUE PODE OCORRER ENTRE CéLULAS DE TUMOR OU CéLULAS NORMAIS E PARA DETERMINAR AS REGIõES OU OS PEPTìDEOS DERIVADOS DE PROTEìNAS VP4, VP8, E, PEPTìDEO". A presente invenção refere-se ao uso de proteínas de rotavírus VP4, VP8 e suas proteínas de fusão e peptídeos derivados, para realçar a liberação de agentes farmacêuticos através do caminho paracelular. Estas proteínas de rotavírus e peptídeos derivados podem ser adicionalmente utilizados para reduzir a adesão celular não desejada que pode ocorrer entre as células cancerosas ou entre as células normais como um resultado de cirurgia, lesão, quimioterapia, doença, inflamação ou outras condições patológicas.
BR0317879-0A 2003-01-10 2003-01-10 Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo BR0317879A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/000280 WO2003098991A2 (en) 2003-01-10 2003-01-10 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability

Publications (1)

Publication Number Publication Date
BR0317879A true BR0317879A (pt) 2005-12-06

Family

ID=29559983

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317879-0A BR0317879A (pt) 2003-01-10 2003-01-10 Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo

Country Status (10)

Country Link
US (1) US8383129B2 (pt)
EP (1) EP1583772B1 (pt)
JP (1) JP4395065B2 (pt)
KR (1) KR101003817B1 (pt)
CN (1) CN100509842C (pt)
AU (1) AU2003201499B2 (pt)
BR (1) BR0317879A (pt)
CA (1) CA2513388C (pt)
MX (1) MXPA05006952A (pt)
WO (1) WO2003098991A2 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004248138B2 (en) * 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
US7491399B2 (en) * 2005-06-23 2009-02-17 University Of Maryland Biotechnology Institute In Ovo vaccine against infectious bursal disease
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
EP2215474A4 (en) * 2007-07-16 2012-07-18 Avaxia Biologics Inc ANTIBODY THERAPY FOR MODULATING THE FUNCTION OF DARM RECEPTORS
EP2725035A1 (en) * 2007-10-02 2014-04-30 Avaxia Biologics, Inc. Antibody therapy for use in the digestive tract
EP2769711A1 (en) * 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
WO2010137900A2 (ko) * 2009-05-27 2010-12-02 전남대학교 산학협력단 선택적 경색 조직 타겟팅 박테리아 및 그의 용도
CN103304642B (zh) * 2013-06-06 2015-01-07 黑龙江八一农垦大学 猪轮状病毒δvp8*亚单位重组蛋白及其应用
KR20210129274A (ko) 2013-09-24 2021-10-27 유니버시티 오브 워싱턴 데스모글레인 2 (dsg2) 결합 단백질 및 그의 용도
CA2875384A1 (en) 2013-12-20 2015-06-20 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CN106167518B (zh) * 2015-05-21 2021-01-15 厦门大学 截短的轮状病毒vp4蛋白及其用途
SG11201907153RA (en) * 2017-02-07 2019-09-27 Lars Erik Peters Topical formulations and methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006971A1 (en) * 1988-02-01 1989-08-10 The Board Of Trustees Of The Leland Stanford Junio Conserved rotavirus gene segments and use in immunization and neutralization
PT100090A (pt) * 1991-02-04 1993-07-30 Univ Saskatchewan Metodo de preparacao de uma composicao capz de libertar um agente biologicamente activo para um alvo, e de encapsulacao do referido agente em esferas da proteina vp6
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US6004534A (en) * 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5525243A (en) 1994-08-31 1996-06-11 Henkel Corporation High cohesion fiber finishes
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5665389A (en) 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
US6777546B2 (en) * 1997-10-07 2004-08-17 Loma Linda University Methods and substances for preventing and treating autoimmune disease
AUPR093000A0 (en) 2000-10-23 2000-11-16 Gibson, David Vincent Improved variable duration camshaft

Also Published As

Publication number Publication date
JP2006513133A (ja) 2006-04-20
KR20050084526A (ko) 2005-08-26
US8383129B2 (en) 2013-02-26
CA2513388A1 (en) 2003-12-04
AU2003201499A1 (en) 2003-12-12
MXPA05006952A (es) 2005-08-16
CN1720262A (zh) 2006-01-11
CA2513388C (en) 2013-06-11
JP4395065B2 (ja) 2010-01-06
KR101003817B1 (ko) 2010-12-28
AU2003201499B2 (en) 2011-06-02
EP1583772A2 (en) 2005-10-12
WO2003098991A3 (en) 2004-02-26
WO2003098991A2 (en) 2003-12-04
EP1583772B1 (en) 2015-04-01
CN100509842C (zh) 2009-07-08
US20060251663A1 (en) 2006-11-09

Similar Documents

Publication Publication Date Title
BR0317879A (pt) Usos da proteìna vp4 de rotavìrus e de anticorpos monoclonais ou policlonais, composição farmacêutica, agente terapêutico, medicamentos, métodos para tratar diabete e câncer, para reduzir a adesão celular não desejada que pode ocorrer entre células de tumor ou células normais e para determinar as regiões ou os peptìdios derivados de proteìnas vp4, vp8, e, peptìdeo
PT1131065E (pt) Fumaratos dialquilicos para o tratamento de doencas autoimunes
BRPI0317376B8 (pt) proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
PE20021151A1 (es) Uso de anticuerpos anti-tnf como farmacos en el tratamiento de trastornos septicos de racientes anemicos
UY28170A1 (es) Preparacion y tratamiento para las enfermedades desmielinizantes y paralisis mediante la aplicacion de agentes remielinizantes.
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
Amantea et al. Early reperfusion injury is associated to MMP2 and IL-1β elevation in cortical neurons of rats subjected to middle cerebral artery occlusion
BRPI0416275A (pt) métodos de tratar, controlar ou prevenir um cáncer especìfico e uma doença associada com angiogênese indesejada
EA200600817A1 (ru) Антагонисты в1 рецептора брадикинина (варианты), фармацевтическая композиция, лекарственное средство, способ лечения заболеваний (варианты)
AU2017225015B2 (en) Medical Use
Loo et al. Discovery of hyperstable noncanonical plant-derived epidermal growth factor receptor agonist and analogs
Haller Update of clinical trials with edrecolomab: a monoclonal antibody therapy for colorectal cancer
Geetha et al. Role of sesamol-loaded floating beads in gastric cancers: a pharmacokinetic and biochemical evidence
Raja Sharin et al. Role of ErbB1 in the underlying mechanism of lapatinib‐induced diarrhoea: A review
Gomes et al. Protection against osteoarthritis in experimental animals by nanogold conjugated snake venom protein toxin gold nanoparticle-Naja kaouthia cytotoxin 1
Liu et al. Dendrimer-based N-acetyl cysteine maternal therapy ameliorates placental inflammation via maintenance of M1/M2 macrophage recruitment
AU2025204816A1 (en) Fibroblasts and microvesicles thereof for reduction of toxicity associated with cancer immunotherapy
RU2446174C2 (ru) Пептид с антипролиферативной активностью и фармацевтическая композиция для лечения пролиферативных заболеваний
Askanase et al. POS0115 DAPIROLIZUMAB PEGOL EFFICACY BY SUBGROUPS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A POST HOC ANALYSIS OF PHASE 2 CLINICAL TRIAL DATA
Lanillos et al. Interrogating the significance of PARP1 expression and PBRM1 mutation as biomarkers for predicting the response to atezolizumab plus bevacizumab or to sunitinib in patients with clear cell renal cell carcinoma
JP2005508875A5 (pt)
EP2507266B1 (en) TREATMENT OF IgE-MEDIATED DISEASE
PT1196188E (pt) Anticorpos monoclonais selectivos para o fcv e sua utilizacao para o tratamento de doencas associadas ao fcv
RU2776047C1 (ru) Способ индуцирования селективной медикаментозной абляции предстательной железы без повреждения нервов и с сохранением половой функции
Weldon What lies beneath the surface of the itch in adults?

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 14A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]